Impax shells out $586 million in Teva's generics sell-off

21 June 2016

USA-based Impax Laboratories (Nasdaq: IPXL) has become the latest company to buy up assets being sold by Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) in a $586 million deal.

Teva is offloading certain assets as a pre-condition of its $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN) to avoid the merged entity breaching competition requirements.

The latest sell-off will see Impax gaining a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms, and regain the rights to the pending abbreviated new drug application (ANDA) for the generic equivalent to the central nervous system stimulant Concerta (methylphenidate hydrochloride).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK